Evidence map›Paper›PMID 37561786›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

ADAM17 targeting by human cytomegalovirus remodels the cell surface proteome to simultaneously regulate multiple immune pathways.

Anzelika Rubina, Mihil Patel, Katie Nightingale, Martin Potts, Ceri A Fielding, Simon Kollnberger, Betty Lau, Kristin Ladell, Kelly L Miners, Jenna Nichols and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  14. Deletion of the non-adjacent genesFrontiers in immunology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Anzelika Rubina *Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0003-4637-609X
Mihil Patel *Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0003-0867-6358
Katie NightingaleCambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom.
Martin PottsCambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom.ORCID 0000-0002-6738-0066
Ceri A FieldingDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-5817-3153
Simon KollnbergerDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Betty LauCentre for Virus Research, University of Glasgow, Glasgow G12 8TA, United Kingdom.
Kristin LadellDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Kelly L MinersDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-7046-6493
Jenna NicholsCentre for Virus Research, University of Glasgow, Glasgow G12 8TA, United Kingdom.ORCID 0000-0003-0093-7170
Luis NobreCambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom.ORCID 0000-0003-0467-8989
Dawn RobertsDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-8411-646X
Terrence M TrincaDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Jason P TwohigDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Virginia-Maria VlahavaDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0003-4233-7739
Andrew J DavisonCentre for Virus Research, University of Glasgow, Glasgow G12 8TA, United Kingdom.ORCID 0000-0002-4991-9128
David A PriceDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Peter TomasecDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.
Gavin W G WilkinsonDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-5623-0126
Michael P WeekesCambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, United Kingdom.ORCID 0000-0003-3196-5545
Richard J Stanton *Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-6799-1182
Eddie C Y Wang *Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom.ORCID 0000-0002-2243-4964
Cardiff University · GBUniversity of Cambridge · GBMRC University of Glasgow Centre for Virus Research · GB

Funding

Medical Research Council MC_UU_12014/3Medical Research Council MR/P001602/1Medical Research Council MR/S00971X/1Medical Research Council MR/V000489/1Wellcome Trust 100326/Z/12/ZWellcome Trust 108070/Z/15/ZWellcome Trust 204870Wellcome Trust 207503/Z/17/Z
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is a major human pathogen whose life-long persistence is enabled by its remarkable capacity to systematically subvert host immune defenses. In exploring the finding that HCMV infection up-regulates tumor necrosis factor receptor 2 (TNFR2), a ligand for the pro-inflammatory antiviral cytokine TNFα, we found that the underlying mechanism was due to targeting of the protease, A Disintegrin And Metalloproteinase 17 (ADAM17). ADAM17 is the prototype 'sheddase', a family of proteases that cleaves other membrane-bound proteins to release biologically active ectodomains into the supernatant. HCMV impaired ADAM17 surface expression through the action of two virally-encoded proteins in its U

Indexed as

CytomegalovirusTumor Necrosis Factor-alphaADAM17 ProteinCell MembraneCytokinesHumansMembrane GlycoproteinsMembrane ProteinsMetalloproteasesProteomeProteomicsReceptors, Tumor Necrosis Factor, Type IIViral Fusion ProteinsViral ProteinsADAM17 ProteinADAM17 protein, humanCytokinesMembrane GlycoproteinsMembrane ProteinsMetalloproteasesProteomeReceptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alphaUL144 ORF protein, Human herpesvirus 5UL148 protein, human cytomegalovirusViral Fusion ProteinsViral ProteinsADAM17Human cytomegalovirusImmune regulation

Identifiers

PMID37561786
PMCPMC10438378
OpenAlexW4385727412

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.